Michael Imevbore, MD
Pulmonary Disease · New Haven, CTNPI 1679660021
Payments from drug & device makers
Across 1,168 payments — averaging $276.28 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- GSK$210K
- AstraZeneca$71K
- Sanofi$27K
- Novartis$5K
- Teva Pharmaceuticals USA, Inc.$2K
- Boehringer Ingelheim$2K
- plus $5K from 30 others
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| GSK | 386 | $210,416 |
| AstraZeneca | 305 | $70,539 |
| Sanofi | 59 | $27,400 |
| Novartis | 39 | $5,061 |
| Teva Pharmaceuticals USA, Inc. | 8 | $2,332 |
| Boehringer Ingelheim | 127 | $2,071 |
| Harmony Biosciences LLC | 24 | $521 |
| Genentech USA, Inc. | 23 | $495 |
| Takeda Pharmaceuticals U.S.A., Inc. | 20 | $484 |
| Mylan Specialty L.p. | 19 | $390 |
| Inspire Medical Systems, Inc. | 9 | $368 |
| Regeneron Healthcare Solutions, Inc. | 15 | $288 |
| Pfizer | 19 | $284 |
| Mallinckrodt Hospital Products Inc. | 13 | $236 |
| Amgen | 8 | $190 |
| Philips North America LLC | 10 | $149 |
| Jazz Pharmaceuticals Inc. | 7 | $147 |
| Grifols USA, LLC | 7 | $145 |
| Sunovion Pharmaceuticals Inc. | 27 | $135 |
| Electromed, Inc. | 6 | $118 |
| Insmed, Inc. | 5 | $117 |
| Avadel CNS Pharmaceuticals, LLC | 5 | $113 |
| Actelion Pharmaceuticals US, Inc. | 4 | $105 |
| Sanofi-aventis U.S. LLC | 1 | $100 |
| Advanced Respiratory, Inc | 3 | $84 |
| Johnson & Johnson | 4 | $69 |
| Shire North American Group Inc | 3 | $67 |
| Lilly USA, LLC | 2 | $61 |
| Baxter Healthcare | 2 | $45 |
| Mallinckrodt Enterprises LLC | 2 | $42 |
| Optinose US, Inc. | 1 | $25 |
| Pulmonx Corporation | 1 | $23 |
| Covis Pharma GmbH | 1 | $21 |
| United Therapeutics Corporation | 1 | $21 |
| E.r. Squibb & Sons, L.L.C. | 1 | $20 |
| Bayer | 1 | $14 |
How this compares
$322,697 in reported general payments places this provider in the 95th percentile of 255 pulmonary disease providers in Connecticut.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Other pulmonary disease in New Haven
- Geoffrey ChuppNew Haven$3.1M
- Jonathan KoffNew Haven$1.1M
- Naftali KaminskiNew Haven$1M
- Danielle Antin-OzerkisNew Haven$1M
- Mridu GulatiNew Haven$536K
- Phillip JosephNew Haven$488K
- Ashley LosierNew Haven$172K
- Lauren CohnNew Haven$156K
- Erica HerzogNew Haven$149K
- Sebastian KurzNew Haven$77K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.